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Background: The causes of fatigue in multiple sclerosis (MS) and other inflammatory
disorders are not well understood. One possible cause that might explain fatigue in
inflammatory disorders appears to be the immunological process itself, triggering neural
activity that is experienced as fatigue.
Objectives: To investigate whether salivary IL-1ß concentration, associated with
systemic inflammation, is related to subjective fatigue in MS.
Methods: 116 MS patients (62 relapsing remitting MS, 54 secondary progressive MS)
and 51 healthy controls participated in this study. Salivary concentration of IL-1ß was
determined using a commercially available enzyme-linked immunosorbent assay (ELISA)
kit. Fatigue was assessed using various fatigue scales.We compared IL-1ß concentration
between groups and performed regression analyses to investigate which variables best
predict fatigue scores.
Results: We found that the IL-1ß concentration best predicts fatigue scores in relapsing
remitting MS patients, even though the IL-1ß concentration did not differ significantly
between relapsing remitting MS patients and healthy controls. Secondary progressive
MS patients showed a somewhat elevated IL-1ß concentration compared to relapsing
remitting MS patients and healthy controls. Furthermore, disease modifying treatment
had a significant effect on the IL-1ß concentration, with treated patients showing a lower
IL-1ß concentration than non-treated patients.
Conclusions: The present study points to a significant relation between the
proinflammatory cytokine IL-1ß and fatigue in relapsing remitting MS patients. It also
suggests a potential effect of disease modifying treatment on the peripheral IL-1ß
concentration.
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INTRODUCTION
Fatigue arguably presents the most challenging symptom for a
majority of multiple sclerosis (MS) patients (1). Its prevalence
ranges from 65 to 97% and it tends to seriously impair
approximately one-third of all MS patients (1–3). Apart from
having negative effects on a patient’s social and private life, fatigue
imposes significant socioeconomic consequences and is a major
reason for the reduction of working hours and early retirement
(4–6). Despite this serious negative impact on daily life activities,
fatigue is still poorly understood and often under-estimated. That
is why we recently developed a model explaining the origin
and consequences of MS-related fatigue (7). According to our
model, subjective fatigue in MS patients is related to peripheral
inflammation. The feeling of fatigue in MS patients is considered
a form of sickness behavior, resulting from cytokine-mediated
activity changes within brain areas involved in interoception such
as the hypothalamus, the amygdala, the insula and the anterior
cingulate. Looking at proinflammatory cytokines, IL-1ß is one of
the main mediators of sickness behavior. IL-1ß activates afferent
vagal neurons and it has been strongly and consistently linked to
symptoms of sickness behavior including fatigue (8–11).
To date, only few studies have investigated the association
between subjective fatigue in MS patients and systemic
inflammation (12–18). Studies investigating the characteristics of
peripheral T lymphocytes frequently found increased production
capacities for proinflammatory cytokines such as IFN-γ and
TNF-α in fatigued MS patients (14, 15, 17). Other studies
reported a higher serum concentration of proinflammatory
cytokines (IL-6, IL-1ß) in patients with high levels of self-
reported fatigue (13, 16). It has been argued that increased
peripheral inflammatory processes cannot explain fatigue in
progressive MS patients since progressive MS is characterized by
diffuse central nervous system atrophy and new inflammatory
lesions are rare in these disease stages (19). In our view, the
fact that there are no relapses any more does not necessarily
imply that there are no underlying inflammatory processes
in the body periphery (19). Hardly any study investigated
the relation between proinflammatory cytokines and fatigue in
chronic disease stages of MS, or compared the proinflammatory
cytokine concentration of MS patients with relapsing-remitting
(rr) and secondary progressive (sp) MS. Hence, we wanted to
investigate whether there is a difference in the concentration of
proinflammatory cytokines between rrMS and spMS patients and
whether proinflammatory cytokines may predict fatigue scores
in MS patients suffering from different clinical disease courses.
Furthermore, few studies indicate that a disease modifying
therapy alters cytokine production in MS patients (20–23). Thus,
we also aimed to investigate whether disease modifying drugs
have an effect on peripheral markers of inflammation.
Most biomarkers that are present in blood and urine can
also be detected in a sample of saliva. Several inflammatory
markers have been reliably determined from saliva and some
studies reported even higher levels of inflammatory markers in
saliva than in blood (24–27). Riis et al. (26) detected higher levels
of the proinflammatory cytokine IL-1ß in saliva than in blood
serum, and they also found a moderate correlation between these
two measures in healthy adolescent girls. Hence, saliva, a non-
invasive method for measuring salivary concentration of IL-1ß,
may be a promising tool for monitoring patients with systemic
inflammatory diseases.
Because we assume that systemic inflammation contributes
to fatigue in rrMS as well as in spMS patients, we compared
the salivary IL-1ß concentration and investigated which variables
best predict fatigue for rrMS and spMS patients.
MATERIALS AND METHODS
Study Population
From August 2015 till the end of June 2017, inpatients of
the Klinikum Bremen-Ost, Bremen, Germany, the Augusta
Hospital Anholt, Anholt, Germany and patients from theMedian
Clinic Wilhelmshaven, Wilhelmshaven, Germany were asked to
participate in the study. Additionally, MS patients were recruited
fromMS support groups in Bremen and surroundings. A total of
116 patients with rrMS (n = 62) and spMS (n = 54) participated
in this multi-center study. Pregnant patients or individuals with
an MS relapse or using corticosteroids during the last 4 weeks
before assessment, under legal care and/or with a diagnosis of
any other neurodegenerative disease were excluded from the
study. Additionally, 51 healthy controls participated. The study
was approved by the ethical board of the German Society of
Psychology (DGP) and written informed consent was obtained
from participants.
Clinical Investigation
Clinical status of all patients was assessed with the Expanded
Disability Status Scale [EDSS; (28)]. Fatigue was assessed with
two self-reported questionnaires, the Fatigue Severity Scale
[FSS; (29)] and the Fatigue Scale for Motor and Cognitive
Functions [FSMC; (30)]. The FSS consists of nine items assessing
severity and frequency of fatigue, with higher scores representing
stronger fatigue. The FSMC evaluates two main components of
fatigue, namely cognitive and motor fatigue. It is composed of 20
items. The cut-off score between normal and mild pathological
fatigue is 43 for the total scale and 22 for the cognitive and motor
scale.
Depressive mood was investigated using the Beck Depression
Inventory Scale [BDI; (31)]. The items A-O, the psychological
items, were used to calculate the score for mood impairment
whereas items P-U (sleep, tiredness, body weight, loss of sexual
interest, somatic concerns) reflect the somatic score and were
excluded from further analysis (32, 33).
Saliva Collection
Participants were asked not to drink, eat, brush their teeth,
smoke or chew gum at least for 1 h prior to the examination
on the day of saliva collection. Whole unstimulated saliva was
collected using standard techniques according to Navazesh (34).
Participants were asked to swallow first, tilt their head forward
and then letting saliva pool in their mouth for 5min. Each
minute, participants were instructed to gently spit their saliva
into a sterile 100ml container. Saliva samples were immediately
refrigerated and stored at−20◦C.
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Salivary IL-1ß Analysis
The analysis of the saliva samples was performed at the
Department of Biochemistry of the Carl von Ossietzky University
Oldenburg. On the day of the analysis, samples were stored
for approx. 30min at room temperature to defrost. 1000 µl
of each sample was pipetted into a tube and centrifuged for
15min at 1000 × g. IL-1ß levels in salivary supernatants
were determined using a commercially available enzyme-linked
immunosorbent assay (ELISA) kit (Quantikine R© ELISA Human
IL-1β/IL-1F2 Immunoassay, R&D Systems, Inc., Minneapolis,
MN, USA) according to the manufacturer’s instructions for
serum/plasma samples. The minimum detectable dose of human
IL-1β is typically less than 1 pg/ml. Samples were analyzed
in duplicate and the absorbance was measured at 450 nm
(wavelength correction was set at 620 nm). The concentration of
the samples was calculated from the standard curve. The results
are presented in picogram per milliliter (pg/ml).
Statistical Analysis
We first checked whether the IL-1ß scores deviated from a
normal distribution using the Kolmogorov-Smirnov Test. As
they were not normally distributed and since the manufacturer
of the ELISA kit recommends laboratory based cut-off values,
we performed an outlier analysis on the IL-1ß results to exclude
possibly spoiled samples from further analyses. This outlier
analysis was based on a boxplot for the healthy control samples
and determined the 1.5 ∗ interquantile score, considering an
IL-1ß concentration beyond 1,200 pg/ml as an outlier (see
Figure 1).
We subsequently compared IL-1ß concentration between
rrMS patients, spMS patients and healthy controls, controlling
for age, gender, depressive mood (psychological item score of the
FIGURE 1 | Boxplot of the salivary concentration of IL-1ß in the whole sample
to determine the upper cut-off scores for excluding possibly spoiled samples.
The error bars reflect the standard deviation. Stars, circles, and numbers
display IL-1β concentration of study participants. rrMS, relapsing remitting
multiple sclerosis; spMS, secondary progressive multiple sclerosis.
BDI) and disease modifying drugs using an univariate analysis of
covariance (ANCOVA).
In a final step, we performed separate linear forward
regression analyses for the three groups to check which variables
best predict the variance in the fatigue scores of rrMS patients,
spMS patients and healthy controls. The fatigue scores were
defined as dependent variables. IL-1ß concentration, age, gender,
number of completed school years, the psychological BDI score
and status on disease modifying treatment were defined as
independent variables.
RESULTS
After applying the cut-off score of IL-1ß concentration <1.200
pg/ml, the salivary IL-1ß concentration showed a normal
distribution. Applying the cut-off score reduced the groups to
45 rrMS patients (73% of the original sample), 35 spMS patients
(65% of the original sample) and 41 healthy controls (80% of the
original sample). Table 1 presents the characteristics and mean
scores of the groups.
There was no significant difference in gender distribution
between the three groups. As expected, spMS patients were
significantly older than rrMS patients and healthy controls, and
they had a longer disease duration and a higher EDSS score
than rrMS patients. Significantly more rrMS patients received
a disease modifying therapy than spMS patients (76 vs. 31%,
p < 0.001). 70% of MS patients suffered frommoderate cognitive
fatigue and 83% suffered from moderate motor fatigue. 64%
had a FSS score higher or equal than 4 indicating pathological
fatigue. RrMS and spMS patients did not differ significantly
in the cognitive fatigue score of the FSMC and the FSS score.
Only on the motor score of the FSMC, spMS patients scored
significantly higher than rrMS patients. 94% of spMS and
76% of rrMS patients suffered from moderate motor fatigue.
Overall, rrMS and spMS scored significantly higher on all
fatigue scores than healthy controls. RrMS patients and healthy
controls did not differ significantly in age. RrMS patients did
not differ significantly on the psychological items score of the
BDI between spMS and healthy controls. But spMS patients
scored significantly higher on the psychological items of the
BDI than healthy controls. There was no significant difference
in the IL-1ß concentration between rrMS patients and healthy
controls or between rrMS and spMS patients. But, spMS patients
presented a significantly higher IL-1ß concentration than healthy
controls.
The ANCOVA on the IL-1ß concentration, controlling for
age, gender, the psychological symptom BDI score and a disease
modifying therapy, revealed a significant Group effect (F= 4.037,
p = 0.020) and a significant effect of a disease modifying
therapy (F = 5.498, p = 0.021). In absolute terms, spMS patients
showed the highest IL-1ß concentration, but post-hoc Bonferroni
corrected t-tests revealed no significant differences between the
groups. Further, MS patients with a disease modifying therapy
had a significantly lower IL-1ß concentration than MS patients
without disease modifying therapy (222.9 vs. 319.9 pg/ml,
p= 0.008). The difference in IL-1ß concentration between treated
and non-treated patients was larger in the group of spMS patients
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(164.8 vs. 353.4 pg/ml, p = 0.001) than in the group of rrMS
patients (241.7 vs. 246.7 pg/ml, p= 0.9; see Figure 2).
The results of the linear forward regression analyses, separate
for groups, are presented in Table 2. The results revealed that
the cognitive fatigue score of the FSMC of rrMS patients is
best predicted by the IL-1ß concentration. The model explains
a significant percentage of the variance of the cognitive fatigue
score (R2 = 0.108, F = 5.223, p= 0.027). The motor fatigue score
of the rrMS patients can be best predicted by a model including
the psychological BDI score, disease modifying therapy and the
concentration of IL-1ß (R2 = 0.438, F = 10.657, p < 0.001). The
FSS score of rrMS patients can be best predicted by a model
including disease modifying therapy, the IL-1ß concentration,
the psychological BDI score and a patient’s age (R2 = 0.439,
F = 7.828, p < 0.001). In all models, the IL-1ß concentration
positively correlated with the fatigue scores (see Figures 3, 4). For
spMS patients, none of the independent variables significantly
predicted fatigue scores of the Fatigue Scale for Motor and
Cognition. The FFS of spMS patients was best predicted by a
model including age (R2 = 0.147, F = 4.294, p = 0.049). For
TABLE 1 | Group characteristics.
rrMS spMS Healthy controls
Male: 7, female: 38 Male: 6, female: 29 Male: 10, female: 31
DMT: 34 (76%) DMT: 11 (31%)
Mean SD Mean SD Mean SD
Age (years)a,c 44.0 10.9 52.1 10.6 41.8 16.2
Time since diagnosis (months)a 111.0 84.8 228.7 103.5
EDSSa 3.4 2.0 5.8 1.5
Cognitive fatigue score (FSMC)b,c 31.8 9.9 33.8 9.7 18.2 7.8
Motor fatigue score (FSMC)a,b,c 34.1 9.2 38.3 6.1 18.5 7.5
Total fatigue score (FSMC)b,c 65.9 17.2 72.1 14.5 36.7 14.8
Fatigue severity scale scoreb,c 42.0 15.6 41.8 15.9 24.4 11.3
Psychological item score (BDI)c 5.2 4.1 6.5 5.2 3.6 4.2
IL-1beta (pg/ml)c 242.9 126.6 294.1 168.1 222.7 138.0
asignificant difference (p < 0.05) between rrMS and spMS.
bsignificant difference (p < 0.05) between rrMS and healthy controls.
csignificant difference (p < 0.05) between spMS and healthy controls.
BDI, beck depression inventory; DMT, disease modifying therapy; EDSS, expanded disability status scale; FSMC, fatigue scale for motor and cognition; rrMS, relapsing remitting multiple
sclerosis; SD, standard deviation; spMS, secondary progressive multiple sclerosis.
FIGURE 2 | Salivary IL-1ß concentration (pg/ml) of healthy controls and of rrMS and spMS patients with and without a disease modifying therapy. Error bars present
the standard deviation. rrMS, relapsing remitting multiple sclerosis; spMS, secondary progressive multiple sclerosis.
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TABLE 2 | Results of the forward regression analyses with the different fatigue scores described as dependent variables.
Relapsing remitting MS patients
DEPENDENT VARIABLE: COGNITIVE FATIGUE SCORE OF THE FSMC
Model Regression coefficient B SD Beta T p
(Constant) 25.558 3.072 8.320 0.000
IL-1ß concentration 0.026 0.011 0.329 2.285 0.027
DEPENDENT VARIABLE: MOTOR FATIGUE SCORE OF THE FSMC
(Constant) 17.941 3.226 5.561 0.000
Psychological BDI score 0.957 0.266 0.424 3.597 0.001
Disease modifying drugs 8.821 2.484 0.416 3.551 0.001
IL-1ß concentration 0.018 0.009 0.254 2.153 0.037
DEPENDENT VARIABLE: FSS SCORE
(Constant) 31.825 9.598 3.316 0.002
Disease modifying drugs 11.939 4.354 0.334 2.742 0.009
IL-1ß concentration 0.051 0.015 0.415 3.398 0.002
Psychological BDI score 1.018 0.454 0.267 2.242 0.031
Age −0.376 0.178 −0.263 −2.113 0.041
Secondary progressive MS patients
DEPENDENT VARIABLE: FSS SCORE
(Constant) 72.421 14.856 4.875 0.000
Age −0.575 0.278 −0.383 −2.072 0.049
Healthy controls
DEPENDENT VARIABLE: COGNITIVE FATIGUE SCORE OF THE FSMC
(Constant) 13.500 1.162 11.637 0.000
Psychological BDI score 1.288 1.288 0.699 6.111 0.000
DEPENDENT VARIABLE: MOTOR FATIGUE SCORE OF THE FSMC
(Constant) 14.548 1.250 11.642 0.000
Psychological BDI score 1.091 0.227 0.611 4.814 0.000
DEPENDENT VARIABLE: FSS SCORE
(Constant) 28.387 4.415 6.430 0.000
Psychological BDI score 1.227 0.380 0.460 3.227 0.003
Age −0.202 0.099 −0.291 −2.044 0.048
BDI, beck depression inventory; FSMC, fatigue scale for motor and cognition; FSS, fatigue severity scale; MS, multiple sclerosis.
healthy controls, the psychological BDI score was included in the
models best predicting the different fatigue scores of the FSMC
(cognitive fatigue score: R2 = 0.489, F = 37.345, p < 0.001;
motor fatigue score: R2 = 0.373, F = 23.179, p < 0.001). The
FSS of healthy controls was best predicted by a model including
the psychological BDI score and age (R2 = 0.251, F = 6.365,
p= 0.004).
DISCUSSION
The results of the present study demonstrated that MS patients
with a secondary progressive disease course showed a somewhat
increased level of IL-1ß in comparison to healthy controls
and rrMS patients. Moreover, we found a significant effect
of disease modifying treatment on the IL-1ß concentration.
Patients receiving such a therapy showed a significantly lower
IL-1ß concentration than patients not receiving such a therapy.
Furthermore, the IL-1ß concentration was one of the main
predictors of fatigue scores in rrMS patients. It did not predict
fatigue scores of spMS patients and healthy controls.
As far as we know, a comparison of peripheral inflammation
between rrMS and spMS patients has not been performed before.
Many reasons may explain the higher IL-1ß level in the spMS
group compared to rrMS patients and healthy controls, which
are irrelevant for the topic of our investigation. To name just a
few: as expected spMS patients showed a high EDSS score (about
6). This may lead to body immobility, less immune competence
and consequently increased IL-1ß values (35). Also, the higher
age of spMS patients might account for an increased level of
systemic proinflammatory cytokines in this group (36). We also
found that receiving a disease modifying therapy has a significant
effect on the IL-1ß concentration. This finding stands in line
with previous studies demonstrating a potential effect of a disease
modifying therapy on cytokine production (20–23). The fact
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FIGURE 3 | Correlation between the salivary IL-1ß concentration (pg/ml) and
the Fatigue Severity Scale Score in relapsing remitting MS patients
(Beta = 0.382, F = 7.3, p = 0.010). rrMS, relapsing remitting multiple
sclerosis.
that less spMS patients than rrMS patients received a disease
modifying therapy may also be relevant for the higher IL-1ß
concentration in spMS patients as compared to rrMS patients
and healthy controls. Irrespectively of the underlying causes for
the increased IL-1ß concentration in spMS patients, the finding
that spMS patients had a somewhat elevated concentration of
IL-1ß might indicate that even in spMS patients there may
be a link between inflammatory activity and the feeling of
fatigue.
The findings of the regression analyses point to a relationship
between the proinflammatory cytokine IL-1ß and fatigue only in
MS patients suffering from a relapsing remitting disease course.
The salivary concentration of IL-1ß was included in all models
best predicting fatigue scores in rrMS patients. This finding
stands in contrast to two previous studies that did not find a
relation between fatigue and blood levels of IL-1ß in MS patients
(16, 37). This difference might be due to the fact that Akali
and colleagues did not use regression analyses to investigate
the relation between fatigue and the IL-1ß concentration. They
did not control for factors such as depression, MS type or
disease modifying drugs (37). Also Malekzadeh et al. did not
consider depressive symptoms in their statistical analysis (16).
We did control for an effect of depressive symptoms on the IL-1ß
concentration. Furthermore, we included a larger amount of MS
patients than the two previous studies and we divided patients
into rrMS and spMS patients and checked for a relationship
between IL-1ß and fatigue in the separate groups. Our results
suggest that especially in the early disease stages of MS, bodily
inflammation may be one dominant cause for fatigue. However,
the relatively low R2 scores indicate that IL-1ß alone may
explain only a limited part of the variance in experienced fatigue.
FIGURE 4 | Correlation between the salivary IL-1ß concentration (pg/ml) and
the Cognitive Fatigue Score of the Fatigue Scale for Motor and Cognition in
relapsing remitting MS patients (Beta = 0.329, F = 5.2, p = 0.027). FSMC,
Fatigue Scale for Motor and Cognition, rrMS, relapsing remitting multiple
sclerosis.
Other cytokines like TNF-α, IL-6, IL-12, or IL-17 may have an
additional impact on subjective fatigue (7).
Overall, fatigue seems to be a multi-factorial symptom
resulting from different causes. Besides immunological
abnormalities, also structural brain changes may contribute
to fatigue. Several studies found a relation between fatigue and
gray matter atrophy within specific brain areas such as frontal
motor areas and subcortical areas such as the thalamus and
basal ganglia (38). Nevertheless, it is noteworthy that in rrMS
patients IL-1ß best predicted fatigue scores, whereas in healthy
controls the psychological items of the BDI appeared to best
predict the variance of the different fatigue scores. Hence, the
level of IL-1ß seems to play an important role in fatigue in rrMS
patients, whereas—as shown in healthy controls—fatigue might
also be related to depressive symptoms as argued in many prior
investigations (39–41).
The absence of a significant difference in IL-1ß concentration
between rrMS patients and healthy controls raises some
questions. One may argue that the peripheral level of IL-1ß
cannot explain subjective fatigue, because then rrMS patients
should show a higher IL-1ß concentration than healthy controls.
The lack of a significant difference in the IL-1ß concentration
between rrMS patients and healthy controls may be due to
the small group sizes. Furthermore, the majority of rrMS
patients received a disease modifying therapy. We found
that patients receiving such a therapy had a significantly
lower IL-1ß concentration. Hence, the lack of a difference
may also be due to fact that most rrMS patients received
a disease modifying therapy. Nevertheless, several studies
show that chronic neuroinflammation sensitizes the brain to
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produce an exaggerated response to peripheral inflammation
resulting in prolonged sickness behavior and increased cytokine
induction within the central nervous system (42, 43). MS
is a chronic inflammatory disease of the central nervous
system which is characterized by chronic peripheral and
central inflammation. Hence, MS patients in general might be
sensitized to the effects of peripheral proinflammatory cytokines.
Consequently, MS patients might produce an exaggerated
response to peripheral inflammation resulting in exaggerated
fatigue, whereas peripheral inflammation has no effect on healthy
controls. This might explain the finding that even though rrMS
and healthy controls present a similar concentration of salivary
IL-1ß, rrMS present significantly higher fatigue scores.
According to the regression analyses, age seems to have an
influence on the Fatigue Severity Scale Score in healthy controls,
rrMS and spMS patients. Age negatively correlated with the
fatigue scores in all groups. This unexpected finding contradicts
the assumption that increased age is related to higher fatigue
scores.
Additional evidence for a relationship between fatigue and
bodily inflammation in MS patients comes from recent studies
in which we demonstrated the importance of inflammation-
induced vagal nerve activity for the generation of fatigue. In
a previous study (44), we found that fatigue severity predicts
future relapses in MS patients, additionally pointing to a relation
between bodily inflammation and fatigue severity in rrMS
patients. We also showed that fatigue in MS patients is associated
with afferent vagal nerve signaling. A disruption of afferent
interoceptive signaling is related to the absence of fatigue in MS
patients (45, 46). Furthermore, fatigue correlates with autonomic
symptoms (47), especially with those that strongly depend on
vagal nerve signaling such as bladder dysfunctions, orthostatic
intolerance and pupillomotor dysfunctions.
Given that an elevated systemic concentration of IL-1ß causes
fatigue in rrMS patients, anti-inflammatory interventions should
have a positive effect on fatigue in this patient population.
Recent studies did show that aerobic exercise and resistance
training have a combined positive effect on proinflammatory
cytokine concentration and on fatigue in mildly impaired MS
patients (48–53). Moreover, substances with anti-inflammatory
properties such as Alfacalcidol, vitamin A or coenzymeQ10 seem
to have the potential to reduce subjective fatigue in MS patients
(54–57). Other studies showed that blocking IL-1ß signaling via
Anakinra, an IL-1ß receptor antagonist exerts a positive effect on
fatigue in patients suffering from inflammatory diseases such as
rheumatoid arthritis or Sjögren’s syndrome (58, 59).
There is another finding of our study, not directly related to
the question of IL-1ß level and fatigue, that should be mentioned.
As expected, rrMS and spMS patients differed in age, disease
duration and EDSS, but not in their total and cognitive fatigue
level. Consequently, the argument that fatigue results from a
loss of function and a compensatory effort to solve everyday
problems is less likely. Only the motor fatigue score showed
a significant difference between the groups. Motor fatigue is
strongly associated to muscle strength and motor impairment
andmight reflect the impact of motor impairment rather than the
actual feeling of fatigue (60, 61). If the compensatory effort model
of fatigue is correct, then it will concern motor fatigue more than
cognitive fatigue.
One limitation of this study is that salivary IL-1ß
concentration may not only reflect systemic immune responses
but also local immune responses. This might explain the high
number of outliers for the salivary IL-1ß concentration scores.
To exclude an extremely high IL-1ß concentration due to
local inflammation in the mouth, oral examinations need to
be included. Nevertheless, gingival crevicular fluid is not only
the result of local cytokine production but it is also a fluid of
systemic origin indicating systemic inflammation. Moreover,
also other factors that were not assessed in this study such as
obesity, smoking or stress may also increase bodily inflammation
and might have influenced the high concentration of IL-1ß in
spMS patients (62–64). Hence, we cannot draw conclusions on
causality regarding the relation between fatigue and IL-1ß in MS
patients. Future studies on inflammatory markers in MS patients
should also check for a potential effect of the above mentioned
factors on peripheral inflammation.
CONCLUSION
We recently developed a model for MS-related fatigue arguing
that the feeling of fatigue is caused by systemic inflammation,
resulting from inflammation-induced activity changes within
interoceptive brain areas (7). The present study points to
an association between the salivary concentration of the
proinflammatory cytokine IL-1ß and subjective fatigue in rrMS
patients. We also found that a disease modifying therapy
significantly lowered the IL-1ß concentration. Future studies
combining immunological and radiological measures are needed
for a better understanding of the relation between subjective
fatigue scores, peripheral immune markers and structural and
functional changes in the central nervous system.
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